ATArmando Tripodi

Armando Tripodi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armando Tripodi has a total of 421 co-authors. Here are the top co-authors by number of shared publications:

  • Veena Chantarangkul

    IRCCS Ca' Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy

    54 shared publications
  • Marigrazia Clerici

    IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

    39 shared publications
  • Pier Mannuccio Mannucci

    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

    30 shared publications
  • Flora Peyvandi

    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

    28 shared publications
  • Massimo Primignani

    Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

    21 shared publications
  • V. Chantarangkul

    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy

    18 shared publications

Latest Publications

  • Open Access

    An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia

    by Niccolò Bitto, Giulia Tosetti, Armando Tripodi, Anna Lecchi, Silvia La Marca, Lidia Padovan, Erica Scalambrino, Marigrazia Clerici, Camilla Caputo, Martina Lucà, et al.

    Background & Aims: Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations. The Total Thrombus Analysis System (T‐TAS) is a flow chamber that can be adapted for thrombocytopenic samples when equipped with the HD‐CHIP. The CirTAS study aimed to assess T‐TAS reproducibility and the ability to identify a disease‐severity gradient in patients with cirrhosis and thrombocytopenia. Methods: Eighty‐one patients with cirrhosis and thrombocytopenia were enrolled (20 Child–Pugh A, 41 B/C and 20 B/C with bacterial infection). T‐TAS measurements were performed using the HD‐CHIP. Reproducibility was assessed by intraclass correlation coefficients. Thromboelastometry (ROTEM) parameters were analysed in parallel. Multivariable and piecewise regression analyses were performed to test factors influencing T‐TAS parameters. Results: T‐TAS showed high reproducibility, with intraclass correlation coefficients ≈0.90 for all parameters ( p < 0.001), even in platelet counts < 50 × 10 9 /L. Thrombus formation under flow declined with worsening clinical status and presence of bacterial infection ( p < 0.05). Alongside, ROTEM showed a trend towards hypocoagulability with increasing disease severity and correlated with T‐TAS parameters. Platelet count and factor VIII (FVIII) were independent determinants of the most representative T‐TAS parameters. Exploratory analyses detected a trend towards a stronger platelet count‐T‐TAS association at 30–50 × 10 9 /L. Conclusions: T‐TAS is reproducible in thrombocytopenic cirrhosis and is associated with reduced thrombus formation alongside disease progression and bacterial infection. Platelet count and FVIII are the main determinants of thrombus formation assessed by T‐TAS.

  • Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection

    by Davide Marotta, Chiara Perucchini, Marta Grillo, Valeria Fumagalli, Pietro Di Lucia, Jordan Rixon, Micol Ravà, Leonardo Giustini, Chiara Malpighi, Giulia D’UOnnolo, et al.

    Elderly individuals affected by COVID-19 are vulnerable to severe respiratory failure for reasons that have remained poorly defined. Here, we show that platelet-released serotonin drives lung pathology in a mouse model of age-associated disease severity after SARS-CoV-2 infection. In middle-aged mice and aged human healthy donors, platelet serotonin release upon activation was enhanced, and increased morbidity with respiratory dysfunction was associated with activated platelets aggregating and promoting fibrin deposition in the lung microvasculature. Pharmacologic or genetic disruption of serotonin uptake, or blockade of serotonin-dependent signaling, attenuated platelet activation and protected against respiratory distress, independently of viral replication and immune responses. Inhibition of fibrin formation similarly reduced disease severity, implicating serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction. Thus, serotonin-mediated platelet procoagulant activity is a major contributor to respiratory insufficiency during SARS-CoV-2 infection and a potential therapeutic target for preserving pulmonary function, particularly in the elderly.

  • A Novel Viscoelastic Tool Highlighting Severity‐Dependent Platelet Dysfunction in Cirrhosis

    by Vincenzo La Mura, Niccolò Bitto, Armando Tripodi

    Key Points: Platelet dysfunction in cirrhosis is influenced by multiple factors, including the severity of liver disease, the acute versus chronic setting, the presence of bacterial infection and organ failure. Thromboelastography (TEG) with Platelet Mapping has identified impaired platelet responsiveness despite elevated levels of von Willebrand factor (VWF) and factor VIII (FVIII), challenging the concept of a universally preserved or compensated haemostatic balance in cirrhosis. Although global haemostatic assays are promising for prognostic assessment, they still require validation against hard clinical outcomes before they can be reliably used to guide bleeding risk stratification in clinical practice.


  • Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates – a cause of concern, awaiting for solution

    by Armando Tripodi, Cristina Novembrino, Flora Peyvandi

    Hemophilia A and B are X-linked hemorrhagic disorders, characterized by low/dysfunctional factor (F)VIII or FIX, respectively. The history of hemophilia treatment has evolved remarkably over time from the introduction of cryoprecipitate in the 1960s to plasma-derived factors in the 1970s. The 1980s brought a tragic chapter, as many plasma-derived products were contaminated with blood-borne viruses. In response to ongoing safety concerns, recombinant factors were developed in the 1990s. However, coagulation factors had a relatively short half-life upon infusion. As technology progressed, extended half-life factors were introduced in the 2010s. More recently, the development of non-transfusional therapies such as emicizumab has revolutionized prophylaxis. Additionally, gene therapy is emerging as a potentially curative approach. Despite these advances, discrepancies in laboratory assays have emerged as a significant challenge. Treatments employing extended half-life products and/or gene therapy, may yield variable results depending on the type of assays used, typically one-stage clotting vs. chromogenic assays. These discrepancies can lead to confusion in monitoring factor levels and assessing treatment outcome. This article aims to review the current situation on results discrepancies recorded when measuring post infusion extended half-life factors with different methods and to provide guidance on options that may be adopted to minimize discrepancies.


  • Open Access

    Direct oral anticoagulants: does one dose fit all? Why, when and how testing

    by Armando Tripodi

    Direct oral anticoagulants (DOAC) are commonly prescribed using fixed-dose regimens, based on the assumption of predictable pharmacokinetics and a favorable balance between efficacy and safety. As a result, laboratory assessment is often considered unnecessary in patients receiving DOAC. However, increasing evidence from clinical trials and real-world studies challenges this “one-dose-fits-all” paradigm, demonstrating marked interindividual variability in drug exposure. Importantly, extreme plasma concentrations have been associated with an increased risk of thrombotic events or bleeding complications. This article revisits the role of the clinical laboratory in the management of patients treated with DOAC, clearly distinguishing routine dose adjustment from targeted measurement in selected clinical scenarios. It discusses situations in which laboratory testing may meaningfully support clinical decision-making, as well as practical considerations regarding DOAC measurement and their interference with commonly used hemostatic assays. Overall, a more nuanced, patient-centered use of laboratory testing may improve the safety and effectiveness of DOAC therapy.


  • Open Access

    Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry

    by Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Sara Arcudi, Roberta Gualtierotti, Cristina Novembrino, Flora Peyvandi


  • Open Access

    Facts and Misfacts on D ‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis ( SISET )

    by Armando Tripodi, Walter Ageno, Luca Barcella, Antonio Coppola, Marcello Di Nisio, Massimo Franchini, Monia Marchetti, Rossella Marcucci, Marco Marietta, Pasquale Pignatelli, et al.

    D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start time‐consuming diagnostic procedures that may generate patient anxiety/distress and often fail to reach meaningful conclusions for patients' management. To make things worse, the incidental finding of unexplained elevated D‐dimer is often, and inadvertently, taken as an index of venous thromboembolism (VTE) that may induce unnecessary initiation of thromboprophylaxis. Finally, population studies showed that elevated D‐dimer is variably associated with arterial thrombosis. However, the above studies do not allow establishing a direct causal relationship between elevated D‐dimer and disease, which makes D‐dimer measurement hardly applicable in individual patients. With this as background, the Italian Society on Thrombosis and Hemostasis appointed a panel to prepare a guidance on the use of D‐dimer based on the literature and expert opinion. The main conclusions of the panel can be summarized as follows: (i) D‐dimer can be reliably used in combination with pre‐test clinical probability to exclude VTE in symptomatic outpatients. (ii) It may help establish the optimal duration of secondary VTE prevention with vitamin K antagonists, although the panel felt that this area needs further investigation when dealing with direct oral anticoagulants. (iv) The use of D‐dimer in combination with the pre‐test probability score can be used to safely rule out acute aortic syndromes in the emergency setting without further imaging tests.


  • Thrombin Generation Assays: What are the Current Clinical Applications?

    by Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Flora Peyvandi

    The thrombin generation assay (TGA), originally developed by McFarlane and Biggs in 1956, was modified in the 2000s by Hemker and coworkers. TGA aims to monitor the continuous generation of thrombin upon activation of coagulation in plasma by the addition of such triggers as small amounts of tissue factor, synthetic phospholipids, and calcium chloride. TGA is sensitive to hypo- and hypercoagulability and is affected by prohemostatic as well as antithrombotic drugs. The review of the current literature shows that TGA is mainly used to investigate conditions characterized by hypo- as well as hypercoagulability and as a laboratory tool to elucidate coagulation mechanisms that are not yet completely understood. This article aims to overview the value and limits of current procedures for TGA for the investigation of hemostasis.


  • Open Access

    The introduction of the international normalized ratio as a breakthrough event in the history of thrombosis

    by Armando Tripodi

    Very few among the youngest readers of this Journal would think about the introduction of the international normalized ratio (INR) as a breakthrough event in the history of thrombosis...